52.00
+1.18(+2.32%)
Currency In USD
| Previous Close | 50.82 |
| Open | 50.51 |
| Day High | 53.3 |
| Day Low | 49.71 |
| 52-Week High | 54.85 |
| 52-Week Low | 20.85 |
| Volume | 752,770 |
| Average Volume | 543,318 |
| Market Cap | 1.93B |
| PE | -400 |
| EPS | -0.13 |
| Moving Average 50 Days | 47.41 |
| Moving Average 200 Days | 38.48 |
| Change | 1.18 |
If you invested $1000 in Harrow Health, Inc. (HROW) 10 years ago, it would be worth $11,403.51 as of February 21, 2026 at a share price of $52. Whereas If you bought $1000 worth of Harrow Health, Inc. (HROW) shares 5 years ago, it would be worth $6,615.78 as of February 21, 2026 at a share price of $52.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026
GlobeNewswire Inc.
Feb 18, 2026 12:00 PM GMT
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on March 3, 2026NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America,
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits
GlobeNewswire Inc.
Feb 17, 2026 12:00 PM GMT
PharmaPack Program to Expand Access to Affordable, FDA-Approved Branded Ophthalmic TherapiesNASHVILLE, Tenn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, t
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
GlobeNewswire Inc.
Feb 02, 2026 12:00 PM GMT
Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting is Proceeding OneHarrow Initiative is Launched to U